Cancer Letters
Volume 297, Issue 1 , Pages 56-64 , 1 November 2010

In vivo antitumor and antimetastatic activities of camptothecin encapsulated with N-trimethyl chitosan in a preclinical mouse model of liver cancer

  • Lina Zhou

      Affiliations

    • Department of Gynecology and Obstetrics, West China Second Hospital, Sichuan University, Chengdu 610041, People’s Republic of China
    • ,
  • Xingyi Li

      Affiliations

    • State Key Laboratory, Biotherapy and Cancer Center, West China Hospital, Sichuan University, Chengdu 610041, People’s Republic of China
    • ,
  • Xiancheng Chen

      Affiliations

    • State Key Laboratory, Biotherapy and Cancer Center, West China Hospital, Sichuan University, Chengdu 610041, People’s Republic of China
    • ,
  • Zhiyong Li

      Affiliations

    • State Key Laboratory, Biotherapy and Cancer Center, West China Hospital, Sichuan University, Chengdu 610041, People’s Republic of China
    • ,
  • Xianping Liu

      Affiliations

    • Department of Gynecology and Obstetrics, West China Second Hospital, Sichuan University, Chengdu 610041, People’s Republic of China
    • ,
  • Shengtao Zhou

      Affiliations

    • Department of Gynecology and Obstetrics, West China Second Hospital, Sichuan University, Chengdu 610041, People’s Republic of China
    • ,
  • Qian Zhong

      Affiliations

    • Department of Gynecology and Obstetrics, West China Second Hospital, Sichuan University, Chengdu 610041, People’s Republic of China
    • ,
  • Tao Yi

      Affiliations

    • Department of Gynecology and Obstetrics, West China Second Hospital, Sichuan University, Chengdu 610041, People’s Republic of China
    • ,
  • Yuquan Wei

      Affiliations

    • State Key Laboratory, Biotherapy and Cancer Center, West China Hospital, Sichuan University, Chengdu 610041, People’s Republic of China
    • ,
  • Xia Zhao

      Affiliations

    • Department of Gynecology and Obstetrics, West China Second Hospital, Sichuan University, Chengdu 610041, People’s Republic of China
    • Corresponding Author InformationCorrespondence to: Xia Zhao, Department of Gynecology and Obstetrics, West China Second Hospital, Sichuan University, No. 20, Section 3, South People’s Road, Chengdu 610041, Sichuan, People’s Republic of China. Tel./fax: +86 28 85501633.
    • ,
  • Zhiyong Qian

      Affiliations

    • State Key Laboratory, Biotherapy and Cancer Center, West China Hospital, Sichuan University, Chengdu 610041, People’s Republic of China
    • Corresponding Author InformationCorrespondence to: Zhiyong Qian, State Key Laboratory, Biotherapy and Cancer Center, West China Hospital, Sichuan University, Keyuan Road 4 No. 1, Gaopeng Street, High Technological Development Zone, Chengdu 610041, Sichuan, People’s Republic of China. Tel.: +86 28 85164063; fax: +86 28 85164060.

Received 13 January 2010 ,Revised 18 April 2010 ,Accepted 27 April 2010.

References 

  1. Sleeman JP. The lymph node as a bridgehead in the metastatic dissemination of tumors. Recent Results Cancer Res. 2000;157:55–81
  2. Tobler NE, Detmar M. Tumor and lymph node lymphangiogenesis: impact on cancer metastasis. J. Leukoc. Biol. 2006;80:691–696
  3. Skobe M, Hawighorst T, Jackson DG, Prevo R, Janes L, Velasco P, et al. Induction of tumor lymphangiogenesis by VEGF-C promotes breast cancer metastasis. Nat. Med. 2001;7:192–198
  4. Stacker SA, Caesar C, Baldwin ME, Thornton GE, Williams RA, Prevo R, et al. VEGF-D promotes the metastatic spread of tumor cells via the lymphatics. Nat. Med. 2001;7:186–191
  5. Gallo RC, Whang-Peng J, Adamson RH. Studies on the antitumor activity, mechanism of action, and cell cycle effects of camptothecin. J. Natl. Cancer Inst. 1971;46:789–795
  6. Herben VM, ten Bokkel Huinink WW, Beijnen JH. Clinical pharmacokinetics of topotecan. Clin. Pharmacokinet. 1996;31:85–102
  7. Hsiang YH, Hertzberg R, Hecht S, Liu LF. Camptothecin induces protein-linked DNA breaks via mammalian DNA topoisomerase I. J. Biol. Chem. 1985;260:14873–14878
  8. van Hattum AH, Pinedo HM, Schluper HM, Erkelens CA, Tohgo A, Boven E. The activity profile of the hexacyclic camptothecin derivative DX-8951f in experimental human colon cancer and ovarian cancer. Biochem. Pharmacol. 2002;64:1267–1277
  9. Wang LM, Li QY, Zu YG, Fu YJ, Chen LY, Lv HY, et al. Anti-proliferative and pro-apoptotic effect of CPT13, a novel camptothecin analog, on human colon cancer HCT8 cell line. Chem. Biol. Interact. 2008;176:165–172
  10. Schluep T, Hwang J, Cheng J, Heidel JD, Bartlett DW, Hollister B, et al. Preclinical efficacy of the camptothecin–polymer conjugate IT-101 in multiple cancer models. Clin. Cancer Res. 2006;12:1606–1614
  11. Lee DH, Kim SW, Suh C, Lee JS, Lee JH, Lee SJ, et al. Belotecan, new camptothecin analogue, is active in patients with small-cell lung cancer: results of a multicenter early phase II study. Ann. Oncol. 2008;19:123–127
  12. Pantazis P, Hinz HR, Mendoza JT, Kozielski AJ, Williams LJ, Stehlin JS, et al. Complete inhibition of growth followed by death of human malignant melanoma cells in vitro and regression of human melanoma xenografts in immunodeficient mice induced by camptothecins. Cancer Res. 1992;52:3980–3987
  13. Potmesil M, Vardeman D, Kozielski AJ, Mendoza J, Stehlin JS, Giovanella BC. Growth inhibition of human cancer metastases by camptothecins in newly developed xenograft models. Cancer Res. 1995;55:5637–5641
  14. Matsuzaki T, Yokokura T, Mutai M, Tsuruo T. Inhibition of spontaneous and experimental metastasis by a new derivative of camptothecin, CPT-11, in mice. Cancer Chemother. Pharmacol. 1988;21:308–312
  15. De Cesare M, Pratesi G, Veneroni S, Bergottoni R, Zunino F. Efficacy of the novel camptothecin Gimatecan against orthotopic and metastatic human tumor xenograft models. Clin. Cancer Res. 2004;10:7357–7364
  16. Sun FX, Tohgo A, Bouvet M, Yagi S, Nassirpour R, Moossa AR, et al. Efficacy of camptothecin analog DX-8951f (Exatecan Mesylate) on human pancreatic cancer in an orthotopic metastatic model. Cancer Res. 2003;63:80–85
  17. Haluska P, Rubin E, Verschraegen CF. Topoisomerase-I inhibitors in gynecologic tumors. Hematol. Oncol. Clin. North Am. 1999;13:43–61
  18. Zu YG, Li QY, Fu YJ, Wang W. Synthesis and cytotoxicity of water soluble quaternary salt derivatives of camptothecin. Bioorg. Med. Chem. Lett. 2004;14:4023–4026
  19. Tardi P, Choice E, Masin D, Redelmeier T, Bally M, Madden TD. Liposomal encapsulation of topotecan enhances anticancer efficacy in murine and human xenograft models. Cancer Res. 2000;60:3389–3393
  20. Kawano K, Watanabe M, Yamamoto T, Yokoyama M, Opanasopit P, Okano T, et al. Enhanced antitumor effect of camptothecin loaded in long-circulating polymeric micelles. J. Control Release. 2006;112:329–332
  21. Chen XC, Lin XJ, Zhao JL, Shi W, Zhang H, Wang YS, et al. A tumor-selective biotherapy with prolonged impact on established metastases based on cytokine gene-engineered MSCs. Mol. Ther. 2008;16:749–756
  22. Isaka N, Padera TP, Hagendoorn J, Fukumura D, Jain RK. Peritumor lymphatics induced by vascular endothelial growth factor-C exhibit abnormal function. Cancer Res. 2004;64:4400–4404
  23. Tsopelas C, Bevington E, Kollias J, Shibli S, Farshid G, Coventry B, et al. 99mTc-Evans blue dye for mapping contiguous lymph node sequences and discriminating the sentinel lymph node in an ovine model. Ann. Surg. Oncol. 2006;13:692–700
  24. Dadras SS, Paul T, Bertoncini J, Brown LF, Muzikansky A, Jackson DG, et al. Tumor lymphangiogenesis: a novel prognostic indicator for cutaneous melanoma metastasis and survival. Am. J. Pathol. 2003;162:1951–1960
  25. Poon RT, Ng IO, Lau C, Yu WC, Yang ZF, Fan ST, et al. Tumor microvessel density as a predictor of recurrence after resection of hepatocellular carcinoma: a prospective study. J. Clin. Oncol. 2002;20:1775–1785
  26. Livak KJ, Schmittgen TD. Analysis of relative gene expression data using real-time quantitative PCR and the 2(-Delta Delta C(T)) method. Methods. 2001;25:402–408
  27. Renyi Vamos F, Tovari J, Fillinger J, Timar J, Paku S, Kenessey I, et al. Lymphangiogenesis correlates with lymph node metastasis, prognosis, and angiogenic phenotype in human non-small cell lung cancer. Clin. Cancer Res. 2005;11:7344–7353
  28. Hall FT, Freeman JL, Asa SL, Jackson DG, Beasley NJ. Intratumoral lymphatics and lymph node metastases in papillary thyroid carcinoma. Arch. Otolaryngol. Head Neck Surg. 2003;129:716–719
  29. Bono P, Wasenius VM, Heikkila P, Lundin J, Jackson DG, Joensuu H. High LYVE-1-positive lymphatic vessel numbers are associated with poor outcome in breast cancer. Clin. Cancer Res. 2004;10:7144–7149
  30. He Y, Rajantie I, Pajusola K, Jeltsch M, Holopaninen T, Yla-Herttuala S, et al. Vascular endothelial cell growth factor receptor 3-mediated activation of lymphatic endothelium is crucial for tumor cell entry and spread via lymphatic vessels. Cancer Res. 2005;65:4739–4746
  31. Schoppmann SF, Birner P, Stockl J, Kalt R, Ullrich R, Caucig C, et al. Tumor-associated macrophages express lymphatic endothelial growth factors and are related to peritumoral lymphangiogenesis. Am. J. Pathol. 2002;161:947–956
  32. Rubbia Brandt L, Terris B, Giostra E, Dousset B, Morel P, Pepper MS. Lymphatic vessel density and vascular endothelial growth factor-C expression correlate with malignant behavior in human pancreatic endocrine tumors. Clin. Cancer Res. 2004;10:6919–6928
  33. Gombos Z, Xu X, Chu CS, Zhang PJ, Acs G. Peritumoral lymphatic vessel density and vascular endothelial growth factor C expression in early-stage squamous cell carcinoma of the uterine cervix. Clin. Cancer Res. 2005;11:8364–8371
  34. Yasuoka H, Nakamura Y, Zuo H, Tang W, Takamura Y, Miyauchi A, et al. VEGF-D expression and lymph vessels play an important role for lymph node metastasis in papillary thyroid carcinoma. Modern Pathol. 2005;18:1127–1133
  35. Oliver G, Detmar M. The rediscovery of the lymphatic system: old and new insights into the development and biological function of the lymphatic vasculature. Genes Dev. 2002;16:773–783
  36. Karpanen T, Egeblad M, Karkkainen MJ, Kubo H, Yla-Herttuala S, Jaattela M, et al. Vascular endothelial growth factor C promotes tumor lymphangiogenesis and intralymphatic tumor growth. Cancer Res. 2001;61:1786–1790
  37. White JD, Hewett PW, Kosuge D, Mcculloch T, Enholm BC, Carmichael J, et al. Vascular endothelial growth factor-D expression is an independent prognostic marker for survival in colorectal carcinoma. Cancer Res. 2002;62:1669–1675
  38. O’Grady A, Dunne C, O’Kelly P, Murphy GM, Leader M, Kay E. Differential expression of matrix metalloproteinase (MMP)-2, MMP-9 and tissue inhibitor of metalloproteinase (TIMP)-1 and TIMP-2 in non-melanoma skin cancer: implications for tumour progression. Histopathology. 2007;51:793–804
  39. Wu ZS, Wu Q, Yang JH, Wang HQ, Ding XD, Yang F, et al. Prognostic significance of MMP-9 and TIMP-1 serum and tissue expression in breast cancer. Int. J. Cancer. 2008;122:2050–2056
  40. Burke TG, Mi Z. The structural basis of camptothecin interactions with human serum album: impact on drug stability. J. Med. Chem. 1994;37:40–46
  41. Wang XH, Cui FZ, Feng QL, Li JC, Zhang YH. Preparation and characterization of collagen/chitosan matrices as potential biomaterials. J. Bioact. Compat. Pol. 2003;18:453–467
  42. Majeti NV, Ravi K. A review of chitin and chitosan applications. React. Funct. Polym. 2000;46:1–27
  43. Thanou M, Verhoef JC, Marbach P, Junginger HE. Intestinal absorption of octreotide: N-trimethyl chitosan chloride (TMC) ameliorates the permeability and absorption properties of the somatostatin analogue in vitro and in vivo. J. Pharm. Sci. 2000;89:951–957

PII: S0304-3835(10)00239-9

doi: 10.1016/j.canlet.2010.04.024

Cancer Letters
Volume 297, Issue 1 , Pages 56-64 , 1 November 2010

Article Tools

* Image Usage & Resolution